The Group delivered a solid southern African operational performance, largely driven by volume growth. The change in case mix from surgical to medical resulted in a lower revenue per paid patient day (PPD) growth.
The weakening of the exchange rate in the first half of the year increased cost pressures on cost of sales and information system licensing fees in the second half of the year. Costs were further impacted by the retrenchment costs in respect of the loss of the Life Esidimeni Gauteng mental health contracts, professional fees incurred on the Healthcare Market inquiry and increasing costs in malpractice insurance.
Poland produced a satisfactory underlying operating performance amidst negative regulatory changes on tariffs that became effective 1 July 2016.
India generated strong EBITDA growth of 29.3%, which was, however, diluted by the additional acquisition funding costs.
The Group invested R763 million (including contingent consideration of R15 million) and R320 million in Poland and India respectively. The Group’s results were impacted by the impairment of R370 million of the Polish investment due to regulatory changes impacting profitability. Earnings continue to be impacted by the dilutive effect of the interest cost on the funding of the international acquisitions.
The southern Africa business added 176 beds (2015: 253), 36 renal dialysis stations and one oncology centre. The Group is focused on expanding the range of services it offers, and remains well positioned to serve the market. Activities, as measured by PPDs, increased by 4.0% as a result of the investment in additional beds and an increase in the length of stay (LOS). The underlying disease burden and ageing medical scheme population continue to drive an increase in hospital utilisation as well as influencing the case mix.
Margins for the year declined to 27.5% (2015: 28.3%), however, key performance indicators remain strong, with weighted occupancies higher at 72.5% (2015: 71.9%).
The Group continued to provide high-quality clinical care as evidenced by good clinical outcomes, hospitalassociated infection rates and patient incident rates in our facilities.
Scanmed expanded its network of facilities through a number of acquisitions during the year, executing on the expansion strategy of its facilities, and continuing to invest in long-term growth opportunities. The Group acquired PGM for R629 million and Carint for R103 million, which were funded from debt raised in Poland.
The Scanmed Group now consists of 624 beds, 12 inpatient cardiology centres and 40 medical facilities.
The Group’s total investment in the business is now R2.2 billion (30 September 2015: R1.4 billion).
EBITDA margins reduced to 10.2% (2015: 14%), due to the negative impact of reduced regulated tariffs for cardiology procedures. Cardiology accounts for approximately 45% of the Scanmed Group business. Further tariff reductions have been announced by the government covering orthopaedic and neurology disciplines. The Group has therefore put on hold its strategy for further investments until there is more clarity from the government in terms of its regulations and the next rounds of contracting. The Group has also changed the senior management team to enable a greater focus on cost management, driving efficiencies, as well as seconding some senior Life Healthcare management to Poland.
The total investment from South Africa into Max is R2.5 billion (30 September 2015: R2.2 billion), which includes an additional R320 million invested during the year to fund the Max Smart acquisition in India by Max. Max added 331 beds during the period, primarily through the acquisition of Max Smart, bringing the number of operational beds to 2 384. The Indian operations reported strong growth with net revenue growing by 16.7% and EBITDA by 29.3%. The growth in revenue was driven by the addition of the 331 beds and an increase in occupancies to 75% (2015: 73%). EBITDA margins improved to 10.9% (2015: 9.9%) on the back of improved occupancies, improved speciality and channel mix and better cost control.
The holding company of Max, Max India Limited, listed in July 2016. The share price at 30 September 2016 gives an approximate value of R5.3 billion for the Group’s stake in Max.
Group revenue increased by 12.0% to R16 404 million (2015: R14 647 million). This is a product of the 8.8% increase in southern African revenue to R15 230 million (2015: R13 999 million) and the growth in revenue from Poland of 81.2% to R1 174 million (2015: R648 million). The southern African Hospital division revenue increased by 9.5% to R14 381 million (2015: R13 133 million) driven by a 4.0% increase in PPDs and a higher revenue per PPD of 5.2%, made up of a 5.9% tariff increase and a 0.7% negative case mix impact. Healthcare Services revenue decreased by 1.9% to R849 million (2015: R866 million) as a result of the phasing out of selected government contracts of the Life Esidimeni business.
Normalised EBITDA¹ increased by 6.6% to R4 314 million (2015: R4 048 million). The EBITDA contribution from Poland was R120 million (2015: R91 million).
|1||Life Healthcare defines normalised EBITDA as operating profit plus depreciation, amortisation of intangible assets, impairment of property, plant and equipment as well as excluding profit/loss and fair value adjustments on disposal of businesses, fair value adjustments, transaction costs and surpluses/deficits on retirement benefits.|
|Operating profit||3 660||3 496|
|Depreciation on property, plant and equipment||530||445|
|Amortisation of intangible assets||147||127|
|Retirement benefit asset and post-employment medical aid||(23)||(20)|
|Normalised EBITDA||4 314||6.6||4 048|
|Southern Africa||4 194||6.0||3 957|
After paying tax of R981 million (2015: R903 million), the Group generated R3 055 million (2015: R2 951 million) in cash from its operating activities. The Group produced strong cash flows from operations, and continues to anticipate positive free cash flow. The overall net cash flow position of the Group is negative, as a result of investing activities, primarily associated with the continuing international investment opportunities of the Group. This net cash outflow was funded through raising debt in South Africa and Poland.
The Group demonstrated a strong financial position against the backdrop of a weak macroeconomic environment. Net debt to normalised EBITDA as at 30 September 2016 was 1.67 times (2015: 1.49 times). This reflects the funding for the Group’s 2016 capital expenditure programme, and the impact of R763 million spent on acquisitions in Poland. The bank covenant for net debt to EBITDA is 2.75 times.
The Max investment of R320 million was funded by available cash resources. Poland funded its acquisitions through the raising of debt in country.
The impairment loss of R370 million recognised during the current year, relates to the Group’s investment in Poland. Contingent consideration in respect of previous Poland acquisitions, of R109 million (2015: R21 million) was released.
Capital expenditure and Investments
During the current financial period, Life Healthcare invested R2 081 million (2015: R3 218 million), comprising capital projects of R1 013 million (2015: R1 181 million), R320 million equity injection for the funding of the acquisition of Max Smart by Max, and R748 million in new acquisitions by Poland. This investment in the Group’s facilities strengthen our service offering, and the new acquisitions are in line with the Group’s focus on expanding our international footprint.
Headline earnings per share (HEPS) and Normalised earnings per share
HEPS increased by 7.0% to 192.5 cps (2015: 179.9 cps). Earnings per share on a normalised basis, which excludes non-trading related items listed below, increased by 2.6% to 182.1 cps (2015: 177.4 cps). The difference in growth between HEPS and normalised earnings per share is as a result of the contingent consideration released in respect of Polish acquisitions which will no longer be payable.
|Profit attributable to ordinary equity holders||1 616||1 866|
|Contingent consideration released||(109)||(21)|
|Impairment of investment||370||–|
|Normalised earnings||1 899||3.3||1 840|
|Normalised EPS (cents)||182.1||2.6||177.4|
|Southern Africa operations (cents)||208.1||194.1|
|International operations (cents)||(1.0)||1.8|
|Funding costs (international acquisitions) (cents)||(25.0)||(18.5)|
Changes to board of directors
There have been no changes to the board of directors for the year ended 30 September 2016.
SCRIP DISTRIBUTION AND CASH DIVIDEND ALTERNATIVE
The board has declared a final distribution for the year ended 30 September 2016, by way of the issue of fully paid Life Healthcare Group Holdings Limited ordinary shares of 0.0001 cent each (the Scrip Distribution) payable to ordinary shareholders (Shareholders) recorded in the register of the Company at the close of business on the Record Date, being Thursday, 15 December 2016.
Shareholders will be entitled, in respect of all or part of their shareholding, to elect to receive a gross cash dividend of 92 cents per ordinary share in lieu of the Scrip Distribution, which will be paid only to those Shareholders who elect to receive the cash dividend, in respect of all or part of their shareholding, on or before 12:00 on Thursday, 15 December 2016 (the Cash Dividend). The Cash Dividend has been declared from income reserves. A dividend withholding tax of 15% will be applicable to all shareholders not exempt therefrom after deduction of which the net Cash Dividend is 78.2 cents per share.
The new ordinary shares will, pursuant to the Scrip Distribution, be settled by way of capitalisation of the Company’s distributable retained profits.
The Company’s total number of issued ordinary shares is 1 057 800 021 as at 10 November 2016. The Company’s Income Tax reference number is 9387/307/15/1.
2. Terms of the Scrip Distribution
The Scrip Distribution will be done at a 2.5% discount to the 15-day volume weighted average price (VWAP). The number of Scrip Distribution shares to which each of the Shareholders will become entitled pursuant to the Scrip Distribution (to the extent that such Shareholders have not elected to receive the Cash Dividend) will be determined by reference to such Shareholder’s ordinary shareholding in Life Healthcare Group Holdings Limited (at the close of business on the Record Date, being Thursday, 15 December 2016) in relation to the ratio that 92 cents multiplied by 1.025 bears to the VWAP of an ordinary Life Healthcare Group Holdings Limited share traded on the JSE during the 15-day trading period ending on Friday, 2 December 2016. Where the application of this ratio gives rise to a fraction of an ordinary share, the number of shares will be rounded up to the nearest whole number if the fraction is 0.5 or more, and rounded down to the nearest whole number if the fraction is less than 0.5.
Details of the ratio will be announced on the Stock Exchange News Service (SENS) of the JSE in accordance with the timetable below.
3. Circular and salient dates
A circular providing shareholders with full information on the Scrip Distribution and the Cash Dividend alternative, including a Form of Election to elect to receive the Cash Dividend alternative will be posted to Shareholders on or about Wednesday, 23 November 2016. The salient dates of events thereafter are as follows:
|Announcement released on SENS in respect of the ratio applicable to the Scrip Distribution, based on the 15-day VWAP ending on Friday, 2 December 2016, by 11h00 on||Monday, 5 December 2016|
|Announcement published in the press of the ratio applicable to the Scrip Distribution, based on the 15-day VWAP ending on Friday, 2 December 2016 on||Tuesday, 6 December 2016|
|Last day to trade in order to be eligible for the Scrip Distribution and the Cash Dividend alternative||Monday, 12 December 2016|
|Ordinary shares trade “ex” the Scrip Distribution and the Cash Dividend alternative on||Tuesday, 13 December 2016|
|Listing and trading of maximum possible number of ordinary shares on the JSE in terms of the Scrip Distribution from the commencement of business on||Tuesday, 13 December 2016|
|Announcement released on SENS in respect of the cash payment for fractional entitlements, based on the VWAP traded on the JSE on Tuesday, 13 December 2016, discounted by 10%||Wednesday, 14 December 2016|
|Last day to elect to receive the Cash Dividend alternative instead of the Scrip Distribution, Forms of Election to reach the Transfer Secretaries by 12h00 on||Thursday, 15 December 2016|
|Record Date in respect of the Scrip Distribution and the Cash Dividend alternative||Thursday, 15 December 2016|
|Scrip Distribution certificates posted and Cash Dividend payments made, CSDP/broker accounts credited/updated, as applicable, on||Monday, 19 December 2016|
|Announcement relating to the results of the Scrip Distribution and the Cash Dividend alternative released on SENS on||Monday, 19 December 2016|
|Announcement relating to the results of the Scrip Distribution and the Cash Dividend alternative published in the press on||Tuesday, 20 December 2016|
|JSE listing of ordinary shares in respect of the Scrip Distribution adjusted to reflect the actual number of ordinary shares issued in terms of the Scrip Distribution at the commencement of business on or about||Wednesday, 21 December 2016|
All times provided are South African local times. The above dates and times are subject to change. Any change will be announced on SENS.
Share certificates may not be dematerialised or rematerialised between Tuesday, 13 December 2016 and Thursday, 15 December 2016, both days inclusive.
COMPETITION COMMISSION MARKET INQUIRY
Life Healthcare has made detailed submissions on the subject matter of the Market Inquiry. Public hearings commenced in February 2016, and Life Healthcare has participated in these hearings. We are yet to receive a revised timetable for the subsequent sets of hearings. This is a large and complex inquiry, and Life Healthcare remains committed to participating in the Healthcare Market Inquiry.
Whilst general market conditions are not expected to improve substantially in the foreseeable future, the Group is well positioned strategically, has the advantage of cost competitive and operationally efficient structures, as well as access to the funding necessary to fulfil its international expansion aspirations.
Southern Africa will take advantage of growth opportunities in 2017 through the addition of 15 acute healthcare beds, 81 mental health beds and through the continued growth in renal dialysis and oncology.
The Group will pursue the development of greenfield facilities and/or acquisitions if they strictly meet our success criteria, and will continue to invest in facilities through upgrades and procurement of equipment.
We will continue to deliver cost-effective care through efficient business processes, optimal resource utilisation and benchmarking of facilities and doctors. A changing external environment reinforces the need to differentiate ourselves through a patient-centric strategy, and focus on clinical outcomes.
Prospects for Poland remain uncertain due to the lack of clarity around pricing impacted by government regulations. The Group will focus on providing excellent clinical quality. In light of sectoral regulatory changes in Poland, the Group will continue to focus on driving further efficiencies, the integration of newly acquired businesses and alignment to the Group’s best operating practices. The effects of these plans, implemented to sustain growth and manage costs, will only be seen over a reasonable period of time.
The Max business relies on the continued success of existing businesses, and on integrating new acquisitions. Specific metrics of growth for the future positioning of Max include a footprint in northern India as well as improving profitability of mature, at-scale hospitals through improvements in specialty/channel mix and cost structures. Max will continue to focus on driving revenue through increasing the number of operational beds, bedding down the Vaishali and Max Smart acquisitions, and improving operational efficiencies.
The contribution of the doctors, nurses and employees of Life Healthcare have greatly enhanced the quality of our performance. We thank them for their contributions.
Approved by the board of directors on 10 November 2016 and signed on its behalf:
Group Chief Executive Officer